Global Gadoterate Meglumine Market

Gadoterate Meglumine Comprehensive Study by Application (Hospitals, Clinics), Distribution Channel (Online e-pharmacies, Offline), End-User (Adult, Pediatrics), Strength (1.8845Gm/5Ml, 3.769Gm/10Ml, 5.6535Gm/15Ml, Others) Players and Region - Global Market Outlook to 2030

Gadoterate Meglumine Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Gadoterate Meglumine
GADOTERATE meglumine (gad oh TER Ate MEG loo meen) is a distinction agent. it's used to diagnose abnormalities during an MRI. Gadoterate meglumine can cause a serious condition in individuals with advanced kidney disease. Gadoterate meglumine is a contrast agent that has magnetic properties. it's used in combination with resonance imaging (MRI) to permit blood vessels, organs, and alternative non-bony tissues to be seen a lot clearer on the imaging. Gadoterate meglumine is used to assist diagnose sure disorders of the brain and spine (central nervous system). Gadoterate meglumine is given as an infusion into a vein.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that European Players will contribute the maximum growth to Global Gadoterate Meglumine market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Guerbet Group (France), GE (United States), Bayer (Germany), Sanochemia (Austria), T2Pharma (Germany), b.e.imaging GmbH (Germany) and Hengrui Medicine (China) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Gadoterate Meglumine market by , Application (Hospitals and Clinics) and Region.



On the basis of geography, the market of Gadoterate Meglumine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel, the sub-segment i.e. Online e-pharmacies will boost the Gadoterate Meglumine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-User, the sub-segment i.e. Adult will boost the Gadoterate Meglumine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Strength, the sub-segment i.e. 1.8845Gm/5Ml will boost the Gadoterate Meglumine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Adoption of The Injection

Market Growth Drivers:
Increasing Need For MRI and Increasing Geriatric Population

Challenges:
Presence of Competitors

Restraints:
Severe Side-Effects Associated with The Medicine

Opportunities:
Increasing Advancement and Innovation

Market Leaders and their expansionary development strategies
November 2020, GE Healthcare has received U.S. FDA approval of its macrocyclic gadolinium-based MRI contrast agent, Clariscan (gadoterate meglumine), in pre-filled syringes. Pre-filled with 10, 15 and 20mL of contrast agent, Clariscan’s ready-assembled, clear plastic syringes save time and reduce the risk of injury from broken glass, while the color-coded volume labels allow for easy identification of the required patient-specific volume. Its 2D data matrix contains scannable key information to be uploaded onto electronic medical systems, reducing the risk of manual data entry errors and helping to further increase workflow efficiency at medical centers.
In April 2020 Guerbet (GBT), a global leader in medical imaging, announced that it received FDA approval to manufacture Dotarem® (gadoterate meglumine) injection.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Gadoterate Meglumine, Venture Capitalists and Private Equity Firms and End-Use Industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Hospitals
  • Clinics
By Distribution Channel
  • Online e-pharmacies
  • Offline

By End-User
  • Adult
  • Pediatrics

By Strength
  • 1.8845Gm/5Ml
  • 3.769Gm/10Ml
  • 5.6535Gm/15Ml
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Need For MRI
      • 3.2.2. Increasing Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. Presence of Competitors
    • 3.4. Market Trends
      • 3.4.1. Increasing Adoption of The Injection
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Gadoterate Meglumine, by Application, Distribution Channel, End-User, Strength and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Gadoterate Meglumine (Value)
      • 5.2.1. Global Gadoterate Meglumine by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Clinics
      • 5.2.2. Global Gadoterate Meglumine by: Distribution Channel (Value)
        • 5.2.2.1. Online e-pharmacies
        • 5.2.2.2. Offline
      • 5.2.3. Global Gadoterate Meglumine by: End-User (Value)
        • 5.2.3.1. Adult
        • 5.2.3.2. Pediatrics
      • 5.2.4. Global Gadoterate Meglumine by: Strength (Value)
        • 5.2.4.1. 1.8845Gm/5Ml
        • 5.2.4.2. 3.769Gm/10Ml
        • 5.2.4.3. 5.6535Gm/15Ml
        • 5.2.4.4. Others
      • 5.2.5. Global Gadoterate Meglumine Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Gadoterate Meglumine (Price)
  • 6. Gadoterate Meglumine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Guerbet Group (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GE (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bayer (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanochemia (Austria)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. T2Pharma (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. B.e.imaging GmbH (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Hengrui Medicine (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Gadoterate Meglumine Sale, by Application, Distribution Channel, End-User, Strength and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Gadoterate Meglumine (Value)
      • 7.2.1. Global Gadoterate Meglumine by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Clinics
      • 7.2.2. Global Gadoterate Meglumine by: Distribution Channel (Value)
        • 7.2.2.1. Online e-pharmacies
        • 7.2.2.2. Offline
      • 7.2.3. Global Gadoterate Meglumine by: End-User (Value)
        • 7.2.3.1. Adult
        • 7.2.3.2. Pediatrics
      • 7.2.4. Global Gadoterate Meglumine by: Strength (Value)
        • 7.2.4.1. 1.8845Gm/5Ml
        • 7.2.4.2. 3.769Gm/10Ml
        • 7.2.4.3. 5.6535Gm/15Ml
        • 7.2.4.4. Others
      • 7.2.5. Global Gadoterate Meglumine Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Gadoterate Meglumine (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Gadoterate Meglumine: by Application(USD Million)
  • Table 2. Gadoterate Meglumine Hospitals , by Region USD Million (2018-2023)
  • Table 3. Gadoterate Meglumine Clinics , by Region USD Million (2018-2023)
  • Table 4. Gadoterate Meglumine: by Distribution Channel(USD Million)
  • Table 5. Gadoterate Meglumine Online e-pharmacies , by Region USD Million (2018-2023)
  • Table 6. Gadoterate Meglumine Offline , by Region USD Million (2018-2023)
  • Table 7. Gadoterate Meglumine: by End-User(USD Million)
  • Table 8. Gadoterate Meglumine Adult , by Region USD Million (2018-2023)
  • Table 9. Gadoterate Meglumine Pediatrics , by Region USD Million (2018-2023)
  • Table 10. Gadoterate Meglumine: by Strength(USD Million)
  • Table 11. Gadoterate Meglumine 1.8845Gm/5Ml , by Region USD Million (2018-2023)
  • Table 12. Gadoterate Meglumine 3.769Gm/10Ml , by Region USD Million (2018-2023)
  • Table 13. Gadoterate Meglumine 5.6535Gm/15Ml , by Region USD Million (2018-2023)
  • Table 14. Gadoterate Meglumine Others , by Region USD Million (2018-2023)
  • Table 15. South America Gadoterate Meglumine, by Country USD Million (2018-2023)
  • Table 16. South America Gadoterate Meglumine, by Application USD Million (2018-2023)
  • Table 17. South America Gadoterate Meglumine, by Distribution Channel USD Million (2018-2023)
  • Table 18. South America Gadoterate Meglumine, by End-User USD Million (2018-2023)
  • Table 19. South America Gadoterate Meglumine, by Strength USD Million (2018-2023)
  • Table 20. Brazil Gadoterate Meglumine, by Application USD Million (2018-2023)
  • Table 21. Brazil Gadoterate Meglumine, by Distribution Channel USD Million (2018-2023)
  • Table 22. Brazil Gadoterate Meglumine, by End-User USD Million (2018-2023)
  • Table 23. Brazil Gadoterate Meglumine, by Strength USD Million (2018-2023)
  • Table 24. Argentina Gadoterate Meglumine, by Application USD Million (2018-2023)
  • Table 25. Argentina Gadoterate Meglumine, by Distribution Channel USD Million (2018-2023)
  • Table 26. Argentina Gadoterate Meglumine, by End-User USD Million (2018-2023)
  • Table 27. Argentina Gadoterate Meglumine, by Strength USD Million (2018-2023)
  • Table 28. Rest of South America Gadoterate Meglumine, by Application USD Million (2018-2023)
  • Table 29. Rest of South America Gadoterate Meglumine, by Distribution Channel USD Million (2018-2023)
  • Table 30. Rest of South America Gadoterate Meglumine, by End-User USD Million (2018-2023)
  • Table 31. Rest of South America Gadoterate Meglumine, by Strength USD Million (2018-2023)
  • Table 32. Asia Pacific Gadoterate Meglumine, by Country USD Million (2018-2023)
  • Table 33. Asia Pacific Gadoterate Meglumine, by Application USD Million (2018-2023)
  • Table 34. Asia Pacific Gadoterate Meglumine, by Distribution Channel USD Million (2018-2023)
  • Table 35. Asia Pacific Gadoterate Meglumine, by End-User USD Million (2018-2023)
  • Table 36. Asia Pacific Gadoterate Meglumine, by Strength USD Million (2018-2023)
  • Table 37. China Gadoterate Meglumine, by Application USD Million (2018-2023)
  • Table 38. China Gadoterate Meglumine, by Distribution Channel USD Million (2018-2023)
  • Table 39. China Gadoterate Meglumine, by End-User USD Million (2018-2023)
  • Table 40. China Gadoterate Meglumine, by Strength USD Million (2018-2023)
  • Table 41. Japan Gadoterate Meglumine, by Application USD Million (2018-2023)
  • Table 42. Japan Gadoterate Meglumine, by Distribution Channel USD Million (2018-2023)
  • Table 43. Japan Gadoterate Meglumine, by End-User USD Million (2018-2023)
  • Table 44. Japan Gadoterate Meglumine, by Strength USD Million (2018-2023)
  • Table 45. India Gadoterate Meglumine, by Application USD Million (2018-2023)
  • Table 46. India Gadoterate Meglumine, by Distribution Channel USD Million (2018-2023)
  • Table 47. India Gadoterate Meglumine, by End-User USD Million (2018-2023)
  • Table 48. India Gadoterate Meglumine, by Strength USD Million (2018-2023)
  • Table 49. South Korea Gadoterate Meglumine, by Application USD Million (2018-2023)
  • Table 50. South Korea Gadoterate Meglumine, by Distribution Channel USD Million (2018-2023)
  • Table 51. South Korea Gadoterate Meglumine, by End-User USD Million (2018-2023)
  • Table 52. South Korea Gadoterate Meglumine, by Strength USD Million (2018-2023)
  • Table 53. Taiwan Gadoterate Meglumine, by Application USD Million (2018-2023)
  • Table 54. Taiwan Gadoterate Meglumine, by Distribution Channel USD Million (2018-2023)
  • Table 55. Taiwan Gadoterate Meglumine, by End-User USD Million (2018-2023)
  • Table 56. Taiwan Gadoterate Meglumine, by Strength USD Million (2018-2023)
  • Table 57. Australia Gadoterate Meglumine, by Application USD Million (2018-2023)
  • Table 58. Australia Gadoterate Meglumine, by Distribution Channel USD Million (2018-2023)
  • Table 59. Australia Gadoterate Meglumine, by End-User USD Million (2018-2023)
  • Table 60. Australia Gadoterate Meglumine, by Strength USD Million (2018-2023)
  • Table 61. Rest of Asia-Pacific Gadoterate Meglumine, by Application USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Gadoterate Meglumine, by Distribution Channel USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Gadoterate Meglumine, by End-User USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Gadoterate Meglumine, by Strength USD Million (2018-2023)
  • Table 65. Europe Gadoterate Meglumine, by Country USD Million (2018-2023)
  • Table 66. Europe Gadoterate Meglumine, by Application USD Million (2018-2023)
  • Table 67. Europe Gadoterate Meglumine, by Distribution Channel USD Million (2018-2023)
  • Table 68. Europe Gadoterate Meglumine, by End-User USD Million (2018-2023)
  • Table 69. Europe Gadoterate Meglumine, by Strength USD Million (2018-2023)
  • Table 70. Germany Gadoterate Meglumine, by Application USD Million (2018-2023)
  • Table 71. Germany Gadoterate Meglumine, by Distribution Channel USD Million (2018-2023)
  • Table 72. Germany Gadoterate Meglumine, by End-User USD Million (2018-2023)
  • Table 73. Germany Gadoterate Meglumine, by Strength USD Million (2018-2023)
  • Table 74. France Gadoterate Meglumine, by Application USD Million (2018-2023)
  • Table 75. France Gadoterate Meglumine, by Distribution Channel USD Million (2018-2023)
  • Table 76. France Gadoterate Meglumine, by End-User USD Million (2018-2023)
  • Table 77. France Gadoterate Meglumine, by Strength USD Million (2018-2023)
  • Table 78. Italy Gadoterate Meglumine, by Application USD Million (2018-2023)
  • Table 79. Italy Gadoterate Meglumine, by Distribution Channel USD Million (2018-2023)
  • Table 80. Italy Gadoterate Meglumine, by End-User USD Million (2018-2023)
  • Table 81. Italy Gadoterate Meglumine, by Strength USD Million (2018-2023)
  • Table 82. United Kingdom Gadoterate Meglumine, by Application USD Million (2018-2023)
  • Table 83. United Kingdom Gadoterate Meglumine, by Distribution Channel USD Million (2018-2023)
  • Table 84. United Kingdom Gadoterate Meglumine, by End-User USD Million (2018-2023)
  • Table 85. United Kingdom Gadoterate Meglumine, by Strength USD Million (2018-2023)
  • Table 86. Netherlands Gadoterate Meglumine, by Application USD Million (2018-2023)
  • Table 87. Netherlands Gadoterate Meglumine, by Distribution Channel USD Million (2018-2023)
  • Table 88. Netherlands Gadoterate Meglumine, by End-User USD Million (2018-2023)
  • Table 89. Netherlands Gadoterate Meglumine, by Strength USD Million (2018-2023)
  • Table 90. Rest of Europe Gadoterate Meglumine, by Application USD Million (2018-2023)
  • Table 91. Rest of Europe Gadoterate Meglumine, by Distribution Channel USD Million (2018-2023)
  • Table 92. Rest of Europe Gadoterate Meglumine, by End-User USD Million (2018-2023)
  • Table 93. Rest of Europe Gadoterate Meglumine, by Strength USD Million (2018-2023)
  • Table 94. MEA Gadoterate Meglumine, by Country USD Million (2018-2023)
  • Table 95. MEA Gadoterate Meglumine, by Application USD Million (2018-2023)
  • Table 96. MEA Gadoterate Meglumine, by Distribution Channel USD Million (2018-2023)
  • Table 97. MEA Gadoterate Meglumine, by End-User USD Million (2018-2023)
  • Table 98. MEA Gadoterate Meglumine, by Strength USD Million (2018-2023)
  • Table 99. Middle East Gadoterate Meglumine, by Application USD Million (2018-2023)
  • Table 100. Middle East Gadoterate Meglumine, by Distribution Channel USD Million (2018-2023)
  • Table 101. Middle East Gadoterate Meglumine, by End-User USD Million (2018-2023)
  • Table 102. Middle East Gadoterate Meglumine, by Strength USD Million (2018-2023)
  • Table 103. Africa Gadoterate Meglumine, by Application USD Million (2018-2023)
  • Table 104. Africa Gadoterate Meglumine, by Distribution Channel USD Million (2018-2023)
  • Table 105. Africa Gadoterate Meglumine, by End-User USD Million (2018-2023)
  • Table 106. Africa Gadoterate Meglumine, by Strength USD Million (2018-2023)
  • Table 107. North America Gadoterate Meglumine, by Country USD Million (2018-2023)
  • Table 108. North America Gadoterate Meglumine, by Application USD Million (2018-2023)
  • Table 109. North America Gadoterate Meglumine, by Distribution Channel USD Million (2018-2023)
  • Table 110. North America Gadoterate Meglumine, by End-User USD Million (2018-2023)
  • Table 111. North America Gadoterate Meglumine, by Strength USD Million (2018-2023)
  • Table 112. United States Gadoterate Meglumine, by Application USD Million (2018-2023)
  • Table 113. United States Gadoterate Meglumine, by Distribution Channel USD Million (2018-2023)
  • Table 114. United States Gadoterate Meglumine, by End-User USD Million (2018-2023)
  • Table 115. United States Gadoterate Meglumine, by Strength USD Million (2018-2023)
  • Table 116. Canada Gadoterate Meglumine, by Application USD Million (2018-2023)
  • Table 117. Canada Gadoterate Meglumine, by Distribution Channel USD Million (2018-2023)
  • Table 118. Canada Gadoterate Meglumine, by End-User USD Million (2018-2023)
  • Table 119. Canada Gadoterate Meglumine, by Strength USD Million (2018-2023)
  • Table 120. Mexico Gadoterate Meglumine, by Application USD Million (2018-2023)
  • Table 121. Mexico Gadoterate Meglumine, by Distribution Channel USD Million (2018-2023)
  • Table 122. Mexico Gadoterate Meglumine, by End-User USD Million (2018-2023)
  • Table 123. Mexico Gadoterate Meglumine, by Strength USD Million (2018-2023)
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Gadoterate Meglumine: by Application(USD Million)
  • Table 132. Gadoterate Meglumine Hospitals , by Region USD Million (2025-2030)
  • Table 133. Gadoterate Meglumine Clinics , by Region USD Million (2025-2030)
  • Table 134. Gadoterate Meglumine: by Distribution Channel(USD Million)
  • Table 135. Gadoterate Meglumine Online e-pharmacies , by Region USD Million (2025-2030)
  • Table 136. Gadoterate Meglumine Offline , by Region USD Million (2025-2030)
  • Table 137. Gadoterate Meglumine: by End-User(USD Million)
  • Table 138. Gadoterate Meglumine Adult , by Region USD Million (2025-2030)
  • Table 139. Gadoterate Meglumine Pediatrics , by Region USD Million (2025-2030)
  • Table 140. Gadoterate Meglumine: by Strength(USD Million)
  • Table 141. Gadoterate Meglumine 1.8845Gm/5Ml , by Region USD Million (2025-2030)
  • Table 142. Gadoterate Meglumine 3.769Gm/10Ml , by Region USD Million (2025-2030)
  • Table 143. Gadoterate Meglumine 5.6535Gm/15Ml , by Region USD Million (2025-2030)
  • Table 144. Gadoterate Meglumine Others , by Region USD Million (2025-2030)
  • Table 145. South America Gadoterate Meglumine, by Country USD Million (2025-2030)
  • Table 146. South America Gadoterate Meglumine, by Application USD Million (2025-2030)
  • Table 147. South America Gadoterate Meglumine, by Distribution Channel USD Million (2025-2030)
  • Table 148. South America Gadoterate Meglumine, by End-User USD Million (2025-2030)
  • Table 149. South America Gadoterate Meglumine, by Strength USD Million (2025-2030)
  • Table 150. Brazil Gadoterate Meglumine, by Application USD Million (2025-2030)
  • Table 151. Brazil Gadoterate Meglumine, by Distribution Channel USD Million (2025-2030)
  • Table 152. Brazil Gadoterate Meglumine, by End-User USD Million (2025-2030)
  • Table 153. Brazil Gadoterate Meglumine, by Strength USD Million (2025-2030)
  • Table 154. Argentina Gadoterate Meglumine, by Application USD Million (2025-2030)
  • Table 155. Argentina Gadoterate Meglumine, by Distribution Channel USD Million (2025-2030)
  • Table 156. Argentina Gadoterate Meglumine, by End-User USD Million (2025-2030)
  • Table 157. Argentina Gadoterate Meglumine, by Strength USD Million (2025-2030)
  • Table 158. Rest of South America Gadoterate Meglumine, by Application USD Million (2025-2030)
  • Table 159. Rest of South America Gadoterate Meglumine, by Distribution Channel USD Million (2025-2030)
  • Table 160. Rest of South America Gadoterate Meglumine, by End-User USD Million (2025-2030)
  • Table 161. Rest of South America Gadoterate Meglumine, by Strength USD Million (2025-2030)
  • Table 162. Asia Pacific Gadoterate Meglumine, by Country USD Million (2025-2030)
  • Table 163. Asia Pacific Gadoterate Meglumine, by Application USD Million (2025-2030)
  • Table 164. Asia Pacific Gadoterate Meglumine, by Distribution Channel USD Million (2025-2030)
  • Table 165. Asia Pacific Gadoterate Meglumine, by End-User USD Million (2025-2030)
  • Table 166. Asia Pacific Gadoterate Meglumine, by Strength USD Million (2025-2030)
  • Table 167. China Gadoterate Meglumine, by Application USD Million (2025-2030)
  • Table 168. China Gadoterate Meglumine, by Distribution Channel USD Million (2025-2030)
  • Table 169. China Gadoterate Meglumine, by End-User USD Million (2025-2030)
  • Table 170. China Gadoterate Meglumine, by Strength USD Million (2025-2030)
  • Table 171. Japan Gadoterate Meglumine, by Application USD Million (2025-2030)
  • Table 172. Japan Gadoterate Meglumine, by Distribution Channel USD Million (2025-2030)
  • Table 173. Japan Gadoterate Meglumine, by End-User USD Million (2025-2030)
  • Table 174. Japan Gadoterate Meglumine, by Strength USD Million (2025-2030)
  • Table 175. India Gadoterate Meglumine, by Application USD Million (2025-2030)
  • Table 176. India Gadoterate Meglumine, by Distribution Channel USD Million (2025-2030)
  • Table 177. India Gadoterate Meglumine, by End-User USD Million (2025-2030)
  • Table 178. India Gadoterate Meglumine, by Strength USD Million (2025-2030)
  • Table 179. South Korea Gadoterate Meglumine, by Application USD Million (2025-2030)
  • Table 180. South Korea Gadoterate Meglumine, by Distribution Channel USD Million (2025-2030)
  • Table 181. South Korea Gadoterate Meglumine, by End-User USD Million (2025-2030)
  • Table 182. South Korea Gadoterate Meglumine, by Strength USD Million (2025-2030)
  • Table 183. Taiwan Gadoterate Meglumine, by Application USD Million (2025-2030)
  • Table 184. Taiwan Gadoterate Meglumine, by Distribution Channel USD Million (2025-2030)
  • Table 185. Taiwan Gadoterate Meglumine, by End-User USD Million (2025-2030)
  • Table 186. Taiwan Gadoterate Meglumine, by Strength USD Million (2025-2030)
  • Table 187. Australia Gadoterate Meglumine, by Application USD Million (2025-2030)
  • Table 188. Australia Gadoterate Meglumine, by Distribution Channel USD Million (2025-2030)
  • Table 189. Australia Gadoterate Meglumine, by End-User USD Million (2025-2030)
  • Table 190. Australia Gadoterate Meglumine, by Strength USD Million (2025-2030)
  • Table 191. Rest of Asia-Pacific Gadoterate Meglumine, by Application USD Million (2025-2030)
  • Table 192. Rest of Asia-Pacific Gadoterate Meglumine, by Distribution Channel USD Million (2025-2030)
  • Table 193. Rest of Asia-Pacific Gadoterate Meglumine, by End-User USD Million (2025-2030)
  • Table 194. Rest of Asia-Pacific Gadoterate Meglumine, by Strength USD Million (2025-2030)
  • Table 195. Europe Gadoterate Meglumine, by Country USD Million (2025-2030)
  • Table 196. Europe Gadoterate Meglumine, by Application USD Million (2025-2030)
  • Table 197. Europe Gadoterate Meglumine, by Distribution Channel USD Million (2025-2030)
  • Table 198. Europe Gadoterate Meglumine, by End-User USD Million (2025-2030)
  • Table 199. Europe Gadoterate Meglumine, by Strength USD Million (2025-2030)
  • Table 200. Germany Gadoterate Meglumine, by Application USD Million (2025-2030)
  • Table 201. Germany Gadoterate Meglumine, by Distribution Channel USD Million (2025-2030)
  • Table 202. Germany Gadoterate Meglumine, by End-User USD Million (2025-2030)
  • Table 203. Germany Gadoterate Meglumine, by Strength USD Million (2025-2030)
  • Table 204. France Gadoterate Meglumine, by Application USD Million (2025-2030)
  • Table 205. France Gadoterate Meglumine, by Distribution Channel USD Million (2025-2030)
  • Table 206. France Gadoterate Meglumine, by End-User USD Million (2025-2030)
  • Table 207. France Gadoterate Meglumine, by Strength USD Million (2025-2030)
  • Table 208. Italy Gadoterate Meglumine, by Application USD Million (2025-2030)
  • Table 209. Italy Gadoterate Meglumine, by Distribution Channel USD Million (2025-2030)
  • Table 210. Italy Gadoterate Meglumine, by End-User USD Million (2025-2030)
  • Table 211. Italy Gadoterate Meglumine, by Strength USD Million (2025-2030)
  • Table 212. United Kingdom Gadoterate Meglumine, by Application USD Million (2025-2030)
  • Table 213. United Kingdom Gadoterate Meglumine, by Distribution Channel USD Million (2025-2030)
  • Table 214. United Kingdom Gadoterate Meglumine, by End-User USD Million (2025-2030)
  • Table 215. United Kingdom Gadoterate Meglumine, by Strength USD Million (2025-2030)
  • Table 216. Netherlands Gadoterate Meglumine, by Application USD Million (2025-2030)
  • Table 217. Netherlands Gadoterate Meglumine, by Distribution Channel USD Million (2025-2030)
  • Table 218. Netherlands Gadoterate Meglumine, by End-User USD Million (2025-2030)
  • Table 219. Netherlands Gadoterate Meglumine, by Strength USD Million (2025-2030)
  • Table 220. Rest of Europe Gadoterate Meglumine, by Application USD Million (2025-2030)
  • Table 221. Rest of Europe Gadoterate Meglumine, by Distribution Channel USD Million (2025-2030)
  • Table 222. Rest of Europe Gadoterate Meglumine, by End-User USD Million (2025-2030)
  • Table 223. Rest of Europe Gadoterate Meglumine, by Strength USD Million (2025-2030)
  • Table 224. MEA Gadoterate Meglumine, by Country USD Million (2025-2030)
  • Table 225. MEA Gadoterate Meglumine, by Application USD Million (2025-2030)
  • Table 226. MEA Gadoterate Meglumine, by Distribution Channel USD Million (2025-2030)
  • Table 227. MEA Gadoterate Meglumine, by End-User USD Million (2025-2030)
  • Table 228. MEA Gadoterate Meglumine, by Strength USD Million (2025-2030)
  • Table 229. Middle East Gadoterate Meglumine, by Application USD Million (2025-2030)
  • Table 230. Middle East Gadoterate Meglumine, by Distribution Channel USD Million (2025-2030)
  • Table 231. Middle East Gadoterate Meglumine, by End-User USD Million (2025-2030)
  • Table 232. Middle East Gadoterate Meglumine, by Strength USD Million (2025-2030)
  • Table 233. Africa Gadoterate Meglumine, by Application USD Million (2025-2030)
  • Table 234. Africa Gadoterate Meglumine, by Distribution Channel USD Million (2025-2030)
  • Table 235. Africa Gadoterate Meglumine, by End-User USD Million (2025-2030)
  • Table 236. Africa Gadoterate Meglumine, by Strength USD Million (2025-2030)
  • Table 237. North America Gadoterate Meglumine, by Country USD Million (2025-2030)
  • Table 238. North America Gadoterate Meglumine, by Application USD Million (2025-2030)
  • Table 239. North America Gadoterate Meglumine, by Distribution Channel USD Million (2025-2030)
  • Table 240. North America Gadoterate Meglumine, by End-User USD Million (2025-2030)
  • Table 241. North America Gadoterate Meglumine, by Strength USD Million (2025-2030)
  • Table 242. United States Gadoterate Meglumine, by Application USD Million (2025-2030)
  • Table 243. United States Gadoterate Meglumine, by Distribution Channel USD Million (2025-2030)
  • Table 244. United States Gadoterate Meglumine, by End-User USD Million (2025-2030)
  • Table 245. United States Gadoterate Meglumine, by Strength USD Million (2025-2030)
  • Table 246. Canada Gadoterate Meglumine, by Application USD Million (2025-2030)
  • Table 247. Canada Gadoterate Meglumine, by Distribution Channel USD Million (2025-2030)
  • Table 248. Canada Gadoterate Meglumine, by End-User USD Million (2025-2030)
  • Table 249. Canada Gadoterate Meglumine, by Strength USD Million (2025-2030)
  • Table 250. Mexico Gadoterate Meglumine, by Application USD Million (2025-2030)
  • Table 251. Mexico Gadoterate Meglumine, by Distribution Channel USD Million (2025-2030)
  • Table 252. Mexico Gadoterate Meglumine, by End-User USD Million (2025-2030)
  • Table 253. Mexico Gadoterate Meglumine, by Strength USD Million (2025-2030)
  • Table 254. Research Programs/Design for This Report
  • Table 255. Key Data Information from Secondary Sources
  • Table 256. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Gadoterate Meglumine: by Application USD Million (2018-2023)
  • Figure 5. Global Gadoterate Meglumine: by Distribution Channel USD Million (2018-2023)
  • Figure 6. Global Gadoterate Meglumine: by End-User USD Million (2018-2023)
  • Figure 7. Global Gadoterate Meglumine: by Strength USD Million (2018-2023)
  • Figure 8. South America Gadoterate Meglumine Share (%), by Country
  • Figure 9. Asia Pacific Gadoterate Meglumine Share (%), by Country
  • Figure 10. Europe Gadoterate Meglumine Share (%), by Country
  • Figure 11. MEA Gadoterate Meglumine Share (%), by Country
  • Figure 12. North America Gadoterate Meglumine Share (%), by Country
  • Figure 13. Global Gadoterate Meglumine share by Players 2023 (%)
  • Figure 14. Global Gadoterate Meglumine share by Players (Top 3) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Guerbet Group (France) Revenue, Net Income and Gross profit
  • Figure 17. Guerbet Group (France) Revenue: by Geography 2023
  • Figure 18. GE (United States) Revenue, Net Income and Gross profit
  • Figure 19. GE (United States) Revenue: by Geography 2023
  • Figure 20. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 21. Bayer (Germany) Revenue: by Geography 2023
  • Figure 22. Sanochemia (Austria) Revenue, Net Income and Gross profit
  • Figure 23. Sanochemia (Austria) Revenue: by Geography 2023
  • Figure 24. T2Pharma (Germany) Revenue, Net Income and Gross profit
  • Figure 25. T2Pharma (Germany) Revenue: by Geography 2023
  • Figure 26. B.e.imaging GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 27. B.e.imaging GmbH (Germany) Revenue: by Geography 2023
  • Figure 28. Hengrui Medicine (China) Revenue, Net Income and Gross profit
  • Figure 29. Hengrui Medicine (China) Revenue: by Geography 2023
  • Figure 30. Global Gadoterate Meglumine: by Application USD Million (2025-2030)
  • Figure 31. Global Gadoterate Meglumine: by Distribution Channel USD Million (2025-2030)
  • Figure 32. Global Gadoterate Meglumine: by End-User USD Million (2025-2030)
  • Figure 33. Global Gadoterate Meglumine: by Strength USD Million (2025-2030)
  • Figure 34. South America Gadoterate Meglumine Share (%), by Country
  • Figure 35. Asia Pacific Gadoterate Meglumine Share (%), by Country
  • Figure 36. Europe Gadoterate Meglumine Share (%), by Country
  • Figure 37. MEA Gadoterate Meglumine Share (%), by Country
  • Figure 38. North America Gadoterate Meglumine Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Guerbet Group (France)
  • GE (United States)
  • Bayer (Germany)
  • Sanochemia (Austria)
  • T2Pharma (Germany)
  • b.e.imaging GmbH (Germany)
  • Hengrui Medicine (China)
Select User Access Type

Key Highlights of Report


Feb 2024 206 Pages 55 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Gadoterate Meglumine Market Quantitative research analysis
Global Gadoterate Meglumine Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Guerbet Group (France), GE (United States), Bayer (Germany), Sanochemia (Austria), T2Pharma (Germany), b.e.imaging GmbH (Germany) and Hengrui Medicine (China) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Adoption of The Injection" is seen as one of major influencing trends for Gadoterate Meglumine Market during projected period 2023-2030.
The Gadoterate Meglumine market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Gadoterate Meglumine Market Report?

Have a Query? Click Here

Other Related Reports

Polyglycol Laxatives Comprehensive Study by Type (Polyglycol 3350, Polyglycol 4000), Application (Chronic Constipation, Irritable Bowel Syndrome, Others), End Users (Adult, Children), Distribution Ch...
$ 3350
Patulin Analysis Comprehensive Study by Type (Ultraviolet Detection, Kit Detection, Others), End-User (Agriculture, Medical, Chemical, Other), Methods (Liquid Chromatography, Diode Array) Players and...
$ 3500
Muscle Invasive Bladder Cancer Comprehensive Study by Application (Hospital, Research Laboratories, Specialty Clinics), Treatment Type (Neo-Adjuvant Chemotherapy, Post-Operative Chemotherapy), Diagno...
$ 3350
Mercury Poisoning Treatment Comprehensive Study by Type (Methylmercury, Elemental Mercury, Others), Application (Hospital Pharmacy, Online Pharmacy, Retailers, Others), Disease (Acute Mercury Poisoni...
$ 3350
Compounding Chemotherapy Comprehensive Study by Type (Pharmaceutical Ingredient Alteration (PIA), Currently Unavailable Pharmaceutical Manufacturing (CUPM), Pharmaceutical Dosage Alteration (PDA)), D...
$ 3750
Medicare Advantage Comprehensive Study by Type (Health maintenance organizations (HMO), Preferred Provider Organizations (PPO), Special Need Plans and Private Fee For Service, Medical Savings Account...
$ 3450